Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Financing › Details

Chr. Hansen–Novozymes: investment, 202212– merger acquisition valuing Chr Hansen at DKK660.55/share ANNOUNCED

 

Period Period 2022-12-12
Organisations Money taker Chr. Hansen Holding A/S
  Group Chr. Hansen (Group)
  Money source Novozymes A/S
  Group Novozymes (Group)
Products Product industrial biotechnology
  Product 2 food ingredient
Person Person Kutay, Kasim (Novo Group 201706 CEO of Novo Holdings A/S)
Document Source Novozymes A/S. (12/12/22). "Press Release: Novozymes and Chr. Hansen to Combine and Create a Leading Global Biosolutions Partner [Not for US, CA, et al.]". Copenhagen.
     

   
Record changed: 2022-12-12

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Chr. Hansen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top